Medical technology company Intelligent Bio Solutions Inc (Nasdaq:INBS) announced on Wednesday that it has secured its sixth US patent, enhancing the protection of its proprietary Intelligent Fingerprinting Drug Screening Cartridge.

The newly granted US Patent No. 12259385 covers the lateral flow test strip inside the cartridge, ensuring that current and future products remain protected under US intellectual property law.

This patent further strengthens the company's comprehensive US intellectual property portfolio, which also includes patents covering the Sample Collection Cartridge, cartridge housing and buffer clip design. Expanded IP protection positions Intelligent Bio Solutions to maintain a competitive edge as it prepares to enter the multi-billion-dollar US drug screening market in 2025.

Intelligent Bio Solutions' Intelligent Fingerprinting Drug Testing Solution uses fingerprint sweat analysis to detect drugs of abuse, addressing growing demand from safety-sensitive industries. The non-invasive, rapid testing technology offers a streamlined alternative to traditional drug testing methods, supporting employee safety and compliance.

Following the company's FDA 510(k) submission in December 2024, Intelligent Bio Solutions is positioned to capitalise on the growing global demand for innovative drug screening solutions.